Price
Change
Open
Date
MPSP
0.45
0.00
N/A
May 17 10:08 am
Founded in 1995, MedPro Safety Products, Inc has developed and acquired a portfolio of patented medical device safety products incorporating proprietary needlestick prevention functionalities. Located in Lexington, Kentucky, MedPro has invested in the future success of the company through patent, regulatory, compliance, acquisition, and marketing efforts. MedPro's core focus, sharps injury risk reduction, is highly competitive and MedPro’s product offerings focus on new “passive” technologies that raise the level of safety for the healthcare worker. MedPro’s product portfolio and intellectual property include four divisions: Pharma, Phlebotomy, Clinical, Intravenous. MedPro is traded on the OTCQB, under the ticker symbol MPSP.
Investor Relations Contact:
The EVC Group
100 Spear Street, Suite 1125
San Francisco, CA 94105
(415) 568-4887
For Investors: Doug Sherk, Jenifer Kirtland
For Media: Chris Gale
Investor Relations Contact:
The EVC Group
100 Spear Street, Suite 1125
San Francisco, CA 94105
(415) 568-4887
For Investors: Doug Sherk, Jenifer Kirtland
For Media: Chris Gale
Investment News
- MedPro Agrees to Sell Patents on Three Blood Collection and Infusion Products to Greiner Bio-One
- MedPro Makes Charitable Donation to Sandy Hook in Lieu of Sending Holiday Cards
- Find MedPro at CPHI in Madrid
- MedPro Safety Products and Weimer Pharma Announce Marketing Partnership
- MedPro Safety Products Signs Letter of Intent with Specialty Pharmaceutical Company
- Crystal Research Provides Update on MedPro Safety Products
- MedPro Safety Products to Participate in Two Key Industry Conferences
- MedPro Featured in Drug Development & Delivery May Issue
- Whitepaper Featured on Occupational Health & Safety Website
- MedPro Safety Products Releases 2011 Financial Results
- Survey Reveals Market Demand for New Prefilled Drug Delivery Platform
- ONdrugDelivery Publication Features MedPro Article
Investment Information
| XBRL Posting | |
| 2011 Annual Report | |
| 2011 Proxy Statement |